Main Content start here
Main Layout
Report Description

Report Description

Forecast Period

2024-2028

Market Size (2022)

USD 4.76 billion

CAGR (2023-2028)

6.76%

Fastest Growing Segment

Diagnostics & Personalized Medicine

Largest Market

United States

 

Market Overview

North America Genotyping Market has valued at USD 4.76 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.76% through 2028. Genotyping is a technique used to detect minor genetic abnormalities that can contribute to significant phenotypic changes, such as physical distinctions that distinguish individuals from one another and pathological changes that underpin disease. It has a wide range of applications in basic science, medicine, and agriculture. By comparing DNA sequences to other sequences, the genotyping test is a widely used method for identifying DNA sequence and genetic composition. Modern genotyping assays include several key properties, such as high efficiency, operational flexibility, and accessibility to several parameters in a single test. Increased funding by governments of various nations to promote genotyping assay methodologies, increased cases of chronic and genetic disorders around the world. Genetic mutations such as single nucleotide variants, copy number variants, and major structural alterations in DNA can all be investigated through genotyping. On a molecular level, high-throughput genomic technologies like next-generation sequencing (NGS) and microarrays can provide a better knowledge of disease etiology. Genotyping data analysis systems may examine results for thousands of indicators and probes and identify sample abnormalities, revealing the functional implications of genetic diversity. In the medical field, genotyping is used to diagnose to prevent the spread of tuberculosis (TB). Initially, genotyping was only used to verify tuberculosis pandemic but, with the advancement of genotyping technology, it can now accomplish much more. Due to advances in genotyping technology, it was discovered that in various tuberculosis cases, infected individuals living in the same house, were not genuinely linked. Due to socio-epidemiological aspects, universal sequencing revealed complex transmission dynamics. As a result, polymerase chain reactions (PCR) were developed, allowing for speedier tuberculosis testing. This approach of quick detection is utilized to avoid tuberculosis. Whole-genome sequencing (WGS) enabled the identification of TB strains, which could subsequently be placed on a historical cluster map. Technological developments, the rising prevalence of cancer and genetic abnormalities, and increased R&D investment for precision medicine research are all contributing to the expansion. Furthermore, the COVID-19 pandemic had a favorable impact on the genotyping market, as increased demand for COVID-19 genotyping kits resulted in the pandemic. The pandemic of COVID-19 has had an enormous influence on the Genotyping business. SNP genotyping is being used to detect SARS-CoV-2 variations, which is increasing market growth. For example, Helen Harper et al. discovered that PACE (PCR Allele Competitive Extension) SNP genotyping techniques provide useful viral genotype detection for SARS-CoV-2 positive samples in a paper published in the PLOS ONE Journal in February 2021.

Key Market Drivers

DNA Sequencing Prices are Decreasing Due to Technological Advances

The genotyping market is experiencing substantial growth, driven in large part by the decreasing prices of DNA sequencing, a trend directly attributed to significant technological advances. This shift has transformative implications for genetics and genomics research, personalized medicine, agriculture, and various other fields. Technological advancements have led to the development of high-throughput sequencing platforms, often referred to as next-generation sequencing (NGS). These platforms allow researchers to simultaneously sequence millions of DNA fragments in parallel, dramatically increasing sequencing efficiency and lowering costs per base. Improved instrumentation, miniaturization, and automation have reduced the upfront costs associated with DNA sequencing. Smaller and more affordable sequencers have made this technology accessible to a broader range of researchers, institutions, and industries.

Decreasing DNA sequencing prices have made genotyping-by-sequencing (GBS) and whole-genome sequencing (WGS) cost-effective alternatives to traditional genotyping methods. Researchers can now obtain detailed genomic information at competitive prices, enabling more comprehensive and precise genotyping. DNA sequencing offers comprehensive genomic data, surpassing the limitations of earlier genotyping methods that focused on specific genetic markers. This allows for a more holistic understanding of genetic variation, including rare and novel variants, contributing to the genotyping market's growth. Falling sequencing costs are pivotal in the advancement of personalized medicine. By obtaining an individual's complete genomic profile, healthcare providers can tailor treatments and interventions to the patient's genetic makeup, improving therapeutic outcomes and reducing adverse reactions. The agriculture sector is increasingly adopting DNA sequencing for genotyping applications. Farmers and breeders utilize genotyping to select superior crop varieties and livestock, optimizing yields and sustainability. In pharmaceutical and biotechnology research, reduced sequencing costs facilitate genotyping studies that identify genetic factors associated with diseases and drug responses. This accelerates drug discovery and development processes.

In conclusion, the decreasing prices of DNA sequencing, driven by technological advances, are a pivotal driver of the genotyping market's growth. These advancements make genotyping more accessible, cost-efficient, and data-rich, benefiting diverse sectors such as healthcare, agriculture, and research. As sequencing technologies continue to evolve, the genotyping market is poised for further expansion, contributing to scientific discoveries and improved applications across various industries.

Increased Genotyping Application Areas

The genotyping market is experiencing remarkable growth, propelled by the increasing application areas and versatility of genotyping technologies. Genotyping, which involves identifying genetic variations within an individual's DNA, has expanded its reach beyond research laboratories to various industries and applications, contributing to the market's rapid expansion. Genotyping plays a pivotal role in personalized medicine. As healthcare shifts towards individualized treatments, genotyping helps healthcare providers tailor medical interventions to a patient's genetic makeup. This includes selecting the most effective drugs and dosages, minimizing adverse reactions, and predicting disease risks. The application of genotyping in cancer genomics has been transformative. By identifying specific genetic mutations or alterations, oncologists can select targeted therapies that are more effective in treating cancer while minimizing damage to healthy cells. Genotyping also aids in predicting the progression of the disease. Genotyping is instrumental in pharmacogenomics, the study of how an individual's genetic makeup influences their response to drugs. This application helps determine the most appropriate medications and dosages for patients, optimizing treatment outcomes and reducing adverse effects. Genotyping has revolutionized agriculture by enabling the selection of superior crop varieties and livestock with desirable genetic traits. This enhances crop yield, disease resistance, and livestock quality, contributing to North America food security and sustainability.

Genotyping is essential in studying genetic diseases and disorders. Researchers use genotyping to identify causative genetic mutations and develop targeted therapies or interventions. This includes diseases like cystic fibrosis, sickle cell anemia, and Huntington's disease. Consumer genotyping services for ancestry and genealogy have gained immense popularity. Individuals use genotyping to explore their genetic heritage, trace their family roots, and connect with distant relatives, driving growth in this application area. Genotyping is indispensable in forensic investigations, aiding in the identification of individuals based on their DNA profiles. It plays a vital role in solving criminal cases, identifying disaster victims, and establishing paternity. Genotyping has expanded into microbiome research, where it helps analyze the genetic composition of microbial communities in various environments. This is crucial for understanding their roles in health, disease, and ecosystems.

The increasing application areas of genotyping technologies reflect their versatility and importance in various sectors, from healthcare to agriculture and beyond. As our understanding of genetics continues to deepen, genotyping is poised to play an even more significant role in shaping the future of medicine, agriculture, and scientific research. This diversification of applications is a driving force behind the sustained growth of the genotyping market.


Download Free Sample Report

Key Market Challenges

The High Cost of Genotyping Equipment

The high cost of genotyping equipment represents a significant challenge for the genotyping market. Genotyping involves the use of specialized laboratory equipment, which can be prohibitively expensive for many research institutions, small biotech companies, and healthcare facilities. Several factors contribute to the cost challenge: Genotyping equipment, such as high-throughput sequencers, microarray scanners, and PCR machines, requires substantial upfront capital investment. The purchase of these instruments can strain the budgets of smaller organizations and research groups. Beyond the initial purchase, maintaining and operating genotyping equipment entails ongoing costs. Regular maintenance, calibration, and the purchase of consumables like reagents, cartridges, and microarrays add to the overall expense. Operating and maintaining genotyping equipment often necessitates specialized training and expertise. Hiring and retaining skilled personnel adds to the cost, making it a resource-intensive endeavor. Processing and analyzing genotyping data generated by expensive equipment require powerful computational resources, further increasing the overall cost. The high cost of genotyping equipment can limit access to cutting-edge genotyping technologies, particularly in lower-resource regions and institutions. This inequality in access hampers North America scientific progress. For many research projects, especially those in academia and smaller biotech startups, budget constraints can make it challenging to afford state-of-the-art genotyping equipment. This limitation may impede scientific advancements.

Addressing the challenge of high equipment costs is essential to ensure broader accessibility and affordability of genotyping technologies. Efforts to reduce costs, promote equipment-sharing initiatives, and provide funding opportunities for research institutions are crucial steps toward overcoming this obstacle. Additionally, advancements in technology and the development of more cost-effective genotyping platforms have the potential to mitigate this challenge, fostering innovation and expanding the genotyping market's reach to a wider range of users and applications.

Lack Of Skilled Labor

The lack of skilled labor is a pressing challenge for the genotyping market. Genotyping techniques and equipment require specialized knowledge and expertise to operate effectively and accurately. The shortage of skilled technicians and researchers with proficiency in genotyping can hinder the adoption and growth of genotyping technologies. It leads to inefficient use of resources, increased error rates, and slower research progress. Addressing this challenge requires investments in education and training programs to cultivate a skilled workforce capable of harnessing the full potential of genotyping technologies, thus ensuring the continued advancement and relevance of the genotyping market.

Ambiguous Reimbursement Policies

Ambiguous reimbursement policies pose a significant challenge for the genotyping market. Genotyping tests and services, especially in the context of personalized medicine, often face uncertainties regarding reimbursement from healthcare payers. These uncertainties can deter healthcare providers from adopting genotyping technologies and offering genotyping-based services to patients. The lack of clear and consistent reimbursement guidelines can lead to variations in coverage and payment, creating financial barriers for patients and providers. Healthcare systems must navigate a complex landscape of reimbursement policies, leading to delays in test adoption and treatment decisions. Additionally, ambiguous policies can hinder investment in genotyping research and development by pharmaceutical and diagnostic companies. Addressing this challenge requires collaborative efforts between policymakers, payers, healthcare providers, and industry stakeholders to establish transparent and standardized reimbursement frameworks that align with the value and potential cost savings associated with genotyping technologies. Clarity in reimbursement policies is vital to ensure that patients have access to cutting-edge genotyping services and to drive innovation in the genotyping market.

Key Market Trends

Expansion of direct-to-consumer genotyping services

The expansion of direct-to-consumer (DTC) genotyping services represents a prominent trend in the genotyping market. DTC genotyping allows individuals to access their genetic information and ancestry insights directly from companies without involving healthcare professionals. Several factors are driving this trend: DTC genotyping empowers individuals to take control of their health and ancestry exploration. It provides accessible and affordable access to personal genetic data, fostering greater awareness and engagement in one's health. Many DTC genotyping companies offer ancestry and genealogy services, attracting consumers interested in discovering their heritage and connecting with distant relatives, contributing to market growth. DTC genotyping provides information on genetic predispositions to certain health conditions and wellness-related traits, driving interest among consumers seeking personalized health recommendations.

The trend also raises concerns about data privacy and security, leading to discussions on regulatory oversight and consumer protection in the genomics space. The vast amount of genetic data collected by DTC companies can be valuable for research and drug development efforts, fostering collaborations between these companies and the broader scientific community. In conclusion, the expansion of DTC genotyping services is reshaping how individuals interact with their genetic information, fostering curiosity about ancestry and health, and providing valuable data for research. As consumers increasingly seek direct access to their genetic data, DTC genotyping is likely to continue as a significant trend in the genotyping market.

Integration of genotyping into clinical diagnostics and healthcare decision-making

The integration of genotyping into clinical diagnostics and healthcare decision-making is a transformative trend in the genotyping market. Genotyping technologies are evolving from research tools to essential components of routine medical practice, with several key factors driving this trend: Genotyping allows for personalized treatment plans tailored to an individual's genetic makeup. Clinicians can use genetic information to select the most effective medications and therapies while minimizing adverse effects, thus optimizing patient outcomes. Genotyping is increasingly being used to assess an individual's genetic predisposition to specific diseases, enabling early intervention and proactive healthcare strategies. Understanding how an individual's genes influence drug metabolism and response is crucial for prescribing the right medications at the right doses. Genotyping helps healthcare providers make more informed decisions, reducing the risk of adverse drug reactions. Genotyping plays a vital role in identifying genetic mutations driving cancer, guiding treatment decisions, and monitoring disease progression. It enables targeted therapies and precision oncology approaches. Some genotyping tests are becoming standard in prenatal care, newborn screening, and other routine healthcare assessments, aiding in the early detection of genetic disorders. As genotyping becomes increasingly integrated into clinical workflows and healthcare decision-making, it enhances the diagnostic accuracy and treatment efficacy across various medical specialties. This trend is likely to continue shaping the genotyping market, promoting the adoption of genotyping technologies in clinical settings, and ultimately improving patient care and outcomes.

Segmental Insights

Product Insights

Based on Product, the market is segmented into Reagents & Kits, Instruments, and Software & Services. The software & service segment recorded a substantial revenue share in the genotyping market in 2021. Due to the increased usage of software-based solutions by testing facilities and academic institutions, the software & services segment is expected to grow at a high rate. Bioinformatics enhances overall efficacy of sequencing procedures and aids in the avoidance of errors that might occur with standard sequencing methods. Agri genomics, animal livestock, human diseases, and microbes all benefit from these services.

Application Insights

Based on Application, the market is segmented into Diagnostics & Personalized Medicine, Agricultural Biotechnology, Pharmacogenomics, Animal Genetics, and Others. The Diagnostics & Personalized segment acquired the highest revenue share in the genotyping market in 2021. It is because of the expanding usage of genotyping products for investigation and the growing need for the identification of genetic illnesses, diagnostics and personalized medicine hold the largest proportion of the genotyping market. Personalized medicine involves the integration of genetic, molecular, and environmental variability into existing approaches to knowledge and management of illnesses.


Download Free Sample Report

Country Insights

Based on Country, the market is segmented into United States, Canada, Mexico. The United States segment garnered the largest revenue share in the genotyping market in 2021. The growing use of advanced technologies, the presence of large pharmaceutical and biopharmaceutical businesses, proactive government policies, and advancements in healthcare infrastructure. Another important aspect contributing to the region's strong market share is the presence of big businesses and authorities investing in genotyping.

Recent Developments

  • Jan-2022: Eurofins Scientific completed the acquisition of Genetic Testing Service JSC, a leading enterprise in genetic testing in Vietnam. This acquisition aimed to improve Eurofins' expansion in Asia and achieve its North America network of clinical diagnosis laboratories concentrated on advanced and specialized genetic testing. Additionally, Gentis has a highly effective test and product menu, which would asset from the Eurofins network's broad catalog of genomic and genetic tests and its approach to additional industries.
  • Jan-2022: Illumina signed a definitive co-development agreement with SomaLogic, a protein biomarker discovery and clinical diagnostics company. Through this agreement, the companies aimed to launch SomaScan Proteomics Assay within Illumina's active & future growth bandwidth next-generation sequencing platforms. Additionally, Illumina would start a multi-year advancement attempt to combine SomaLogic's protein objective volume with Illumina's arranging technologies, DRAGEN, and informatics toolsets software to generate a complete end-to-end NGS functionality solution.
  • Aug-2021: Thermo Fisher Scientific introduced a TaqMan SARS-CoV-2 Mutation Panel to identify the Delta and Lambda strains. The advanced biosystem allows laboratories to record known mutations by choosing from more than 50 assays intended to screen for various variants. Additionally, the biosystem is extremely ascendable, permitting up to hundreds of samples to be tested to recognize one or various mutations so labs can measure observation tasks based on testing requirements.
  • Apr-2021: Bio-Rad Laboratories unveiled the ddPCR Assays for AAV Viral Titer and the Vericheck ddPCR Mycoplasma Detection Kit. The two assays support the production and advancement of safe and adequate cell and gene treatments. Moreover, ddPCR product offerings in the gene and cell treatment space reverse overall dedication to informing the North America requirement for effective and safe healing.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Agilent Technologies, Inc
  • Thermo Fisher Scientific, Inc
  • Qiagen N.V
  • Illumina, Inc
  • Bio-Rad laboratories, Inc
  • Eurofins Scientific Group
  • Fluidigm Corporation
  • GE Healthcare Inc

By Product

By Technology

By Application

By End use

By Country

  • Reagents & Kits
  • Instruments
  • Software & Services
  • PCR
  • Sequencing
  • Capillary Electrophoresis
  • Microarray
  • Mass Spectrometry
  • Others
  • Diagnostics & Personalized Medicine
  • Agricultural Biotechnology
  • Pharmacogenomics
  • Animal Genetics
  • Others
  • Diagnostics & Research Laboratories
  • Pharmaceutical & Biopharmaceutical Companies
  • Academic Institutes
  • Others
  • United States
  • Canada
  • Mexico

 

Report Scope:

In this report, the North America Genotyping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • North America Genotyping Market, By Product:

o   Reagents & Kits

o   Instruments

o   Software & Services

  • North America Genotyping Market, By Technology:

o   PCR

o   Sequencing

o   Capillary Electrophoresis

o   Microarray

o   Mass Spectrometry

o   Others

  • North America Genotyping Market, By Application:

o   Diagnostics & Personalized Medicine

o   Agricultural Biotechnology

o   Pharmacogenomics

o   Animal Genetics

o   Others

  • North America Genotyping Market, By End use:

o   Diagnostics & Research Laboratories

o   Pharmaceutical & Biopharmaceutical Companies

o   Academic Institutes

o   Others

  • North America Genotyping Market, By Country:

o   United States

o   Canada

o   Mexico

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the North America Genotyping Market.

Available Customizations:

North America Genotyping market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

North America Genotyping Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]               

Table of content

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    North America Genotyping Market Outlook

5.1.  Market Size & Forecast

5.1.1.    By Value

5.2.  Market Share & Forecast

5.2.1.    By Product (Reagents & Kits, Instruments, Software & Services)

5.2.2.    By Technology (PCR, Sequencing, Capillary Electrophoresis, Microarray, Mass Spectrometry, Others)

5.2.3.    By Application (Diagnostics & Personalized Medicine, Agricultural Biotechnology, Pharmacogenomics, Animal Genetics, Others)

5.2.4.    By End use (Diagnostics & Research Laboratories, Pharmaceutical & Biopharmaceutical Companies, Academic Institutes, Others)

5.2.5.    By Country

5.2.6.    By Company (2022)

5.3.  Market Map

6.    United States Genotyping Market Outlook

6.1.1.1.        Market Size & Forecast

6.1.1.1.1.           By Value

6.1.1.2.        Market Share & Forecast

6.1.1.2.1.           By Product

6.1.1.2.2.           By Technology

6.1.1.2.3.           By Application

6.1.1.2.4.           By End use

7.    Canada Genotyping Market Outlook

7.1.  Market Size & Forecast

7.1.1.    By Value

7.2.  Market Share & Forecast

7.2.1.    By Product

7.2.2.    By Technology

7.2.3.    By Application

7.2.4.    By End use

8.    Mexico Genotyping Market Outlook

8.1.  Market Size & Forecast

8.1.1.    By Value

8.2.  Market Share & Forecast

8.2.1.    By Product

8.2.2.    By Technology

8.2.3.    By Application

8.2.4.    By End use

9.    Market Dynamics

9.1.  Drivers & Challenges

10. Market Trends & Developments

10.1.   Recent Developments

10.2.   Product Launches

10.3.   Mergers & Acquisition

11. North America Genotyping Market: SWOT Analysis

12. Competitive Landscape

12.1.   F. Hoffmann-La Roche Ltd.

12.1.1.    Business Overview

12.1.2.    Treatment Offerings

12.1.3.    Recent Developments

12.1.4.    Key Personnel

12.1.5.    SWOT Analysis

12.2.   Danaher Corporation

12.3.   Agilent Technologies, Inc

12.4.   Thermo Fisher Scientific, Inc

12.5.   Qiagen N.V

12.6.   Illumina, Inc

12.7.   Bio-Rad laboratories, Inc

12.8.   Eurofins Scientific Group

12.9.   Fluidigm Corporation

12.10.GE Healthcare Inc

13. Strategic Recommendations

14. About Us & Disclaimer

Figures and Tables

Frequently asked questions

Frequently asked questions

The market size of the North America Genotyping Market was estimated to be USD 4.76 billion in 2022.

Genotyping is the process of identifying and analyzing an individual's genetic variations, typically by examining specific DNA markers or genetic loci, to gain insights into their genetic characteristics and traits.

F. Hoffmann-La Roche Ltd, Danaher Corporation, Agilent Technologies, Inc, Thermo Fisher Scientific, Inc, Qiagen N.V, Illumina, Inc, Bio-Rad laboratories, Inc, Eurofins Scientific Group, Fluidigm Corporation, GE Healthcare Inc are the top players operating in the North America Genotyping Market in 2022.

Rising Prevalence Of Genetic And Other Target Diseases and Increasing Focus On Development Of Targeted Drugs And Personalized Medicine are the major drivers for the North America Genotyping Market.

Related Reports